Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | RORB | Q92753 | 4/20 | 0.45 |
| ▸ | RORC | P51449 | 3/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724483 | 0.83 | PARP1 (0.59) | PARP1RORBRORCKIF11KDM4E | |
| SCHEMBL353488 | 0.80 | BCAT2 (0.53) | PARP1KDM4EMAPT | |
| SCHEMBL5694476 | 0.78 | PARP1 (0.54) | PARP1RORBRORCKIF11KDM4E | |
| SCHEMBL30272163 | 0.77 | RORB (0.66) | PARP1RORBRORCKIF11KDM4E | |
| SCHEMBL4683411 | 0.77 | RORB (0.66) | PARP1RORBRORCKIF11KDM4E | |
| SCHEMBL28202997 | 0.74 | RORB (0.57) | PARP1RORBRORCKIF11KDM4E | |
| SCHEMBL5964891 | 0.74 | PARP1 (0.56) | PARP1RORBRORCKIF11KDM4E | |
| SCHEMBL5074291 | 0.73 | PARP1 (0.60) | PARP1RORBRORCKIF11KDM4E | |
| SCHEMBL3455274 | 0.72 | PLG (0.54) | PARP1KIF11KDM4ECNR2JAK2 | |
| SCHEMBL8337607 | 0.71 | KIF11 (0.57) | PARP1KIF11KDM4ECNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | PARP1 2623/4885RORB 1710/4885RORC 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.